Correction

Correction to: Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment

D. Gouty,^{1,17} C. C. Cai,² X. Y. Cai,³ A. Kasinath,⁴ V. Kumar,⁵ S. Alvandkouhi,⁶ J. Yang,⁷ S. Pederson,⁸ B. Babbitt,⁹ D. Peritt,¹⁰ A. Rudy,¹¹ V. Koppenburg,¹² A. Dasilva,¹³ M. Ullmann,¹⁴ S. Liu,¹⁵ and C. Satterwhite¹⁶

Published online 27 February 2018

Correction to: AAPS J

<https://doi.org/10.1208/s12248-017-0181-6>

In the published article, the author B. Babbitt was cited as affiliation 2, but should have been cited as affiliation 9. In addition, there are 2 errors in the affiliations. The correct affiliations are shown in this erratum.

The online version of the original article can be found at <https://doi.org/10.1208/s12248-017-0181-6>

¹ BioAgilytix Labs, Durham, North Carolina, USA.

² Pfizer Inc, Groton, Connecticut, USA.

³ WuXi AppTec Co. Ltd, Shanghai, China.

⁴ Syngene International Ltd, Bangalore, India.

⁵ Biologics, Dr. Reddy's Laboratories Ltd., Hyderabad, India.

⁶ BioAgilytix Labs, Durham, North Carolina, USA.

⁷ Genentech, Inc, South San Francisco, California, USA.

⁸ Alder Biopharmaceuticals Inc., Bothell, Washington, USA.

⁹ PAREXEL International Corp, Waltham, Massachusetts, USA.

¹⁰ Pfizer Inc, Cambridge, Massachusetts, USA.

¹¹ Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany.

¹² Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany.

¹³ Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany.

¹⁴ Merck KGaA, Geneva, Switzerland.

¹⁵ Apobiologix, Toronto, Ontario, Canada.

¹⁶ Charles River Laboratory, Reno, Nevada, USA.

To whom correspondence should be addressed. (e-mail: dominique.gouty@bioagilytix.com)